A university lab got a non-catalog research peptide made to a spec its journal would accept — without standing up its own scale-up
An academic neuroscience lab had a promising custom sequence but no way to make enough of it, to a documented identity and purity standard, for the next phase of in vivo work. PeptideXpo's custom-synthesis route closed that gap on the lab's experimental timeline.
Published May 10, 2026 · Anonymized customer story
Material type
Non-catalog custom sequence
Analytical packet
Identity + purity + contaminant, per batch
Timeline impact
Experimental schedule kept intact
Repeat orders
Route on file, no re-qualification
Challenge
The lab had an early in vitro result on a custom peptide that wasn't in any reference database, and the next phase needed substantially more material than its in-house synthesis core could turn out on schedule. The Principal Investigator's real constraint was downstream: the eventual publication and the animal-protocol review both required documented identity, purity, and contaminant testing on the actual batch used — not a generic catalog spec. So the material had to come with a paper trail strong enough to survive peer review and protocol scrutiny, which ruled out an unsupported bulk buy.
Approach
We countersigned a mutual NDA quickly and treated this as a custom-synthesis program: a small pilot lot first, with the full analytical packet — high-purity HPLC, mass-spec identity confirmation against the theoretical mass, tandem-MS sequence verification across the ion ladder (essential for a sequence with no database entry), and endotoxin and microbial-limit testing on the batch. The lab's QC signed off the pilot, and we ran the larger campaign in parallel with the lab's own validation so the two timelines overlapped instead of stacking. Both lots were held under observation across the dosing period to confirm the material held its profile.
Outcome
The lab moved from sequence brief to a validated, study-ready batch on a timeline that kept its experimental schedule intact, and the analytical package it received covered the disclosures its target journal's methods section treats as non-negotiable. The synthesis route is now on file for repeat orders, so subsequent batches for the same program don't restart qualification from scratch.
“The thing we couldn't compromise on was documentation our reviewers and our protocol committee would accept — for a sequence that isn't in any database, the tandem-MS sequence confirmation mattered as much as the purity number. Getting study-ready material on our timeline, with that packet attached, is exactly what we needed.”